Cell line · CVCL_1161
Papers21
1 to 20 of 21
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| A Conserved Enhancer Locus in Extrachromosomal DNA and Homogeneously Staining Regions Activates MYC Transcription in Group 3 Medulloblastoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Transcriptional regulation of protein synthesis by mediator kinase represents a therapeutic vulnerability in MYC-driven medulloblastoma. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Single-cell multi-omics identifies metabolism-linked epigenetic reprogramming as a driver of therapy-resistant medulloblastoma. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Metastatic medulloblastoma remodels the local leptomeningeal microenvironment to promote further metastatic colonization and growth. | Nat Cell Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Single-cell multi-omics analysis identifies metabolism-linked epigenetic reprogramming as a driver of therapy-resistant medulloblastoma | Res Sq | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Transcriptional Regulation of Protein Synthesis by Mediator Kinase Represents a Therapeutic Vulnerability in MYC-driven Medulloblastoma | Res Sq | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. | Mol Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. | bioRxiv | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma. | Cancers (Basel) | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Transcriptional control of DNA repair networks by CDK7 regulates sensitivity to radiation in MYC-driven medulloblastoma. | Cell Rep | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Role of MYC-miR-29-B7-H3 in Medulloblastoma Growth and Angiogenesis. | J Clin Med | 2019 | Its Methods give the RRID and name the line | PubMed | |
| Data on the number and frequency of scientific literature citations for established medulloblastoma cell lines. | Data Brief | 2016 | Cellosaurus cites it | PubMed | |
| In vitro models of medulloblastoma: Choosing the right tool for the job. | J Biotechnol | 2016 | Cellosaurus cites it | PubMed | |
| BET bromodomain inhibition of MYC-amplified medulloblastoma. | Clin Cancer Res | 2014 | Cellosaurus cites it | PubMed | |
| MDM2 antagonism by nutlin-3 induces death in human medulloblastoma cells. | Neurosci Lett | 2012 | Cellosaurus cites it | PubMed | |
| Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma. | Neuro Oncol | 2010 | Cellosaurus cites it | PubMed | |
| Signatures of mutation and selection in the cancer genome. | Nature | 2010 | Cellosaurus cites it | PubMed | |
| Chromosomal characteristics of childhood brain tumors. | Cancer Genet Cytogenet | 1997 | Cellosaurus cites it | PubMed | |
| Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts. | Lab Invest | 1991 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1161/papers